Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is a heterogeneous cancer in which sorafenib is the only approved systemic therapy. Histone deacetylases (HDAC) are commonly dysregulated in cancer and therefore represent promising targets for therapies, however their role in HCC pathogenesis is...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Lachenmayer, Anja, Toffanin, Sara, Cabellos, Laia, Alsinet, Clara, Hoshida, Yujin, Villanueva, Augusto, Minguez, Beatriz, Tsai, Hung-Wen, Ward, Stephen C., Thung, Swan, Friedman, Scott L., Llovet, Josep M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2012
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3355195/
https://ncbi.nlm.nih.gov/pubmed/22322234
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jhep.2012.01.009
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia